Immunosuppressive Strategies in Lung Transplantation

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 May 2

PMID 32355853

Citations 16

Authors

Paul A Chung

Daniel F Dilling

Affiliations

Soon will be listed here.

Abstract

Lung transplantation is a viable option for those with end-stage lung disease which is evidenced by the continued increase in the number of lung transplantations worldwide. However, patients and clinicians are constantly faced with acute and chronic rejection, infectious complications, drug toxicities, and malignancies throughout the lifetime of the lung transplant recipient. Conventional maintenance immunosuppression therapy consisting of a calcineurin inhibitor (CNI), anti-metabolite, and corticosteroids have become the standard regimen but newer agents and modalities continue to be developed. Here we will review induction agents, maintenance immunosuppressives, adjunctive therapies and other strategies to improve long-term outcomes.

Citing Articles

The role of induction therapy in lung transplantation.

Landino S, Nawalaniec J, Hays N, Osho A, Keller B, Allan J Am J Transplant. 2024; 25(3):463-470.

PMID: 39551266 PMC: 11842198. DOI: 10.1016/j.ajt.2024.11.011.

Time to Rethink Bronchiolitis Obliterans Syndrome Following Lung or Hematopoietic Cell Transplantation in Pediatric Patients.

Jaing T, Wang Y, Chiu C Cancers (Basel). 2024; 16(21).

PMID: 39518153 PMC: 11545638. DOI: 10.3390/cancers16213715.

Intensive care unit-acquired weakness - preventive, and therapeutic aspects; future directions and special focus on lung transplantation.

Sunder T World J Clin Cases. 2024; 12(19):3665-3670.

PMID: 38994273 PMC: 11235433. DOI: 10.12998/wjcc.v12.i19.3665.

Pharmacodynamic monitoring by residual gene expression of the nuclear factor of activated T cell-regulated genes in lung transplant recipients and its correlation with tacrolimus blood levels.

Boada-Perez M, Ruiz de Miguel V, Erro M, Ussetti P, Aguilar M, Castejon R Front Immunol. 2024; 15:1382459.

PMID: 38799459 PMC: 11116644. DOI: 10.3389/fimmu.2024.1382459.

Quality of life and its association with predictors in lung transplant recipients: a latent profile analysis.

Song L, Luo Q, Liu C, Zhou Y, Huang D, Ju C Front Public Health. 2024; 12:1355179.

PMID: 38741913 PMC: 11089158. DOI: 10.3389/fpubh.2024.1355179.

References

Kingah P, Muma G, Soubani A . Azithromycin improves lung function in patients with post-lung transplant bronchiolitis obliterans syndrome: a meta-analysis. Clin Transplant. 2014; 28(8):906-10. DOI: 10.1111/ctr.12401. View

Sacher V, Fertel D, Srivastava K, Panos A, Nguyen D, Baxter T . Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients. Ann Thorac Surg. 2013; 97(1):268-74. DOI: 10.1016/j.athoracsur.2013.07.072. View

HARDY J, Webb W, Dalton Jr M, WALKER Jr G . LUNG HOMOTRANSPLANTATION IN MAN. JAMA. 1963; 186:1065-74. DOI: 10.1001/jama.1963.63710120001010. View

Johnson B, Iacono A, Zeevi A, McCurry K, Duncan S . Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003; 167(9):1271-8. DOI: 10.1164/rccm.200205-410OC. View

Gottlieb J, Neurohr C, Muller-Quernheim J, Wirtz H, Sill B, Wilkens H . A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation. Am J Transplant. 2019; 19(6):1759-1769. PMC: 6590654. DOI: 10.1111/ajt.15251. View

Verleden G, Dupont L . Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004; 77(9):1465-7. DOI: 10.1097/01.tp.0000122412.80864.43. View

Li Y, Gottlieb J, Ma D, Kuehn C, Strueber M, Welte T . Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation--a propensity score analysis with 23 years of follow-up. Transplantation. 2011; 92(4):486-92. DOI: 10.1097/TP.0b013e318225670d. View

King-Biggs M, Dunitz J, Park S, Kay Savik S, Hertz M . Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 2003; 75(9):1437-43. DOI: 10.1097/01.TP.0000064083.02120.2C. View

Federica M, Nadia S, Monica M, Alessandro C, Tiberio O, Francesco B . Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin Transplant. 2011; 25(4):E381-9. DOI: 10.1111/j.1399-0012.2011.01435.x. View

10.

Shitrit D, Bendayan D, Sulkes J, Bar-Gil Shitrit A, Huerta M, Kramer M . Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med. 2005; 99(5):596-601. DOI: 10.1016/j.rmed.2004.09.023. View

11.

Iacono A, Johnson B, Grgurich W, Youssef J, Corcoran T, Seiler D . A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006; 354(2):141-50. DOI: 10.1056/NEJMoa043204. View

12.

Fan Y, Xiao Y, Weng Y . Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplant Proc. 2009; 41(5):1821-4. DOI: 10.1016/j.transproceed.2008.11.016. View

13.

Ruttens D, Verleden S, Vandermeulen E, Bellon H, Vanaudenaerde B, Somers J . Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial. Am J Transplant. 2015; 16(1):254-61. DOI: 10.1111/ajt.13417. View

14.

Wehman B, Griffith B, Balwan A, Kon Z, Suffredini D, Evans C . Long-term outcomes following alemtuzumab induction in lung transplantation. Heart Surg Forum. 2013; 16(5):E252-6. DOI: 10.1532/HSF98.2013160. View

15.

Mian M, Natori Y, Ferreira V, Selzner N, Husain S, Singer L . Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients. Clin Infect Dis. 2017; 66(9):1392-1397. DOI: 10.1093/cid/cix1008. View

16.

Patel N, Cook A, Greenhalgh E, Rech M, Rusinak J, Heinrich L . Overview of extended release tacrolimus in solid organ transplantation. World J Transplant. 2016; 6(1):144-54. PMC: 4801790. DOI: 10.5500/wjt.v6.i1.144. View

17.

Jain R, Hachem R, Morrell M, Trulock E, Chakinala M, Yusen R . Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2010; 29(5):531-7. PMC: 2854291. DOI: 10.1016/j.healun.2009.12.003. View

18.

Yates B, Murphy D, Forrest I, Ward C, Rutherford R, Fisher A . Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005; 172(6):772-5. DOI: 10.1164/rccm.200411-1537OC. View

19.

Hall E, Engels E, Pfeiffer R, Segev D . Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2014; 99(5):1051-7. PMC: 4405385. DOI: 10.1097/TP.0000000000000449. View

20.

Penninga L, Moller C, Penninga E, Iversen M, Gluud C, Steinbruchel D . Antibody induction therapy for lung transplant recipients. Cochrane Database Syst Rev. 2013; (11):CD008927. PMC: 6486205. DOI: 10.1002/14651858.CD008927.pub2. View